関連する実験動画

Updated: Feb 17, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

2025年の腎不全:2025年の腎不全:2025年における腎不全:2025年における腎不全:2025年における腎不全:2025年における腎不全:2025年における腎不全:2025年における腎不全:2025年における腎不全:2025年に

Dominique Stephan¹, Emma Morisot¹, François Bronner²

¹Service d'HTA et Maladies Vasculaires, Hôpitaux Universitaires de Strasbourg, France.

International journal of cardiology. Cardiovascular risk and prevention

|February 16, 2026

まとめ

腎不全 (RDN) は,3年以上にわたって制御されない高血圧の持続的な血圧低下を提供します. この安全な治療法は,高リスクの患者にとって有望であり,腎動脈の問題は観察されていません.

科学分野:

心血管医学心血管医学
介入性心臓病学介入性心臓病学
高血圧管理高血圧管理について

背景:

腎不全 (RDN) は,耐性高血圧に対する新興のデバイスベースの治療法です.
最近の大規模な心臓血管学会議では,RDNの有効性と安全性に関する3年間のフォローアップデータが提示されました.
制御されていない高血圧は,革新的な治療戦略を必要とする重要な世界的な健康上の課題であり続けています.

研究の目的:

制御されていない高血圧の腎不全 (RDN) に関する3年間のフォローアップデータを合成する.
ランダム化試験と実世界の登録データに基づいて,RDNの持続的有効性と安全性を評価する.
血圧制御と急性高血圧イベントに対するRDNの影響を評価する.

主な方法:

SPYRAL HTN-ON MED,GSR-DEFINEレジストリ,SPYRAL AFFIRM,およびプール分析から得られたデータの統合.
ランダム化された偽薬対照試験と観察登録データの比較.
3年間のフォローアップで,オフィスシストリック血圧 (SBP) の低下と急性高血圧イベントの分析.

主要な成果:

持続的なオフィス SBP の減少は -18.5 mmHg の RDN と対照的に -11.7 mmHg のシャムで 3 年 (SPYRAL HTN-ON MED).
グローバルシンプリシティ・レジストリDEFINEは,3年後にオフィスSBPの -20.5 mmHgの減少を示し,効果は時間とともに増加しました.
プール分析は,急性高血圧イベントの43%の減少を示し,腎動脈狭窄または再介入は不要でした.

結論:

RDNは,制御不能高血圧の選択された患者に耐久的で安全な補助療法を示しています.
RDNの利点は,糖尿病,CKD,前脳卒中を含む高リスク集団に広がっています.
長期的な心血管疾患のアウトカムデータはまだ未定ですが,最初の結果は有望です.

キーワード:

腎臓の消化症は腎臓の消化症である.交感性神経系は,交感性神経系である.制御できない高血圧.

さらに関連する動画

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats

Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats

Published on: September 11, 2018

関連する概念動画

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Neural Regulation of Blood Pressure

Neural Regulation of Blood Pressure

The neural regulation of blood pressure involves intricate interactions between the autonomic nervous system (ANS) and cardiovascular system, ensuring adequate perfusion of tissues. This regulation primarily occurs through baroreceptor and chemoreceptor reflexes, involving both short-term and long-term mechanisms.
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Hypertension and Regulation of Blood Pressure

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...